FT
RARE icon

Fiduciary Trust’s Ultragenyx Pharmaceutical RARE Stock Holding History

Fiduciary Trust’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$533K Sell
15,962
-1,237
-7% -$30.7K 0.01% 587
2026
Q1 		$360K Buy
17,199
+931
+6% +$21K ﹤0.01% 680
2025
Q4 		$374K Buy
16,268
+3,152
+24% +$104K ﹤0.01% 650
2025
Q3 		$395K Buy
13,116
+6,139
+88% +$184K ﹤0.01% 619
2025
Q2 		$254K Buy
6,977
+55
+0.8% +$1.98K ﹤0.01% 726
2025
Q1 		$251K Buy
+6,922
New +$288K ﹤0.01% 716

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Fiduciary Trust's RARE Position: Q2 2026 in Review

Fiduciary Trust reduced its Ultragenyx Pharmaceutical (RARE) stake by 7.2% in Q2 2026, selling an estimated $30.7K and leaving 15,962 shares worth $533K. The position accounts for 0.01% of the portfolio, ranked #587.

Fiduciary Trust first reported a position in RARE in Q1 2025 and has held it in 6 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Fiduciary Trust held 15,962 shares of Ultragenyx Pharmaceutical worth $533K as of Q2 2026.
  • Fiduciary Trust sold 1,237 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $30.7K.
  • Ultragenyx Pharmaceutical made up 0.01% of Fiduciary Trust's portfolio in Q2 2026, its #587 holding.
  • Fiduciary Trust first reported a position in Ultragenyx Pharmaceutical in Q1 2025 and has held it in 6 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.